Literature DB >> 12113827

Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity.

James J Chambers1, Deborah M Kurrasch-Orbaugh, David E Nichols.   

Abstract

Positional modification of 2,5-dimethoxyamphetamine analogues has been studied. Specifically, the 5-alkoxy substituent was translocated to the 6-position of the phenyl nucleus. Methoxy groups were also constrained by incorporation into appended dihydrofuran and furan rings. 2,6-Dimethoxy-4-methylamphetamine had an approximately 3-fold lower affinity for the 5-HT(2A) receptor compared to the parent 2,5-dimethoxy-4-methylamphetamine (DOM). The rigid compound based on the 2,3,5,6-tetrahydrobenzo[1,2-b;5,4-b']difuran nucleus and the aromatic analogue containing the benzo[1,2-b;5,4-b']difuran nucleus possessed an approximate 7- and 27-fold increase in affinity, respectively, compared to 2,6-dimethoxy-4-methylamphetamine, the non-rigid, positional isomer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113827     DOI: 10.1016/s0960-894x(02)00306-2

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines.

Authors:  Danielle M Schultz; Jennifer A Prescher; Stephanie Kidd; Danuta Marona-Lewicka; David E Nichols; Aaron Monte
Journal:  Bioorg Med Chem       Date:  2008-05-06       Impact factor: 3.641

2.  Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines.

Authors:  Karolina E Kolaczynska; Dino Luethi; Daniel Trachsel; Marius C Hoener; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2019-11-28       Impact factor: 5.810

3.  Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines.

Authors:  Karolina E Kolaczynska; Dino Luethi; Daniel Trachsel; Marius C Hoener; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.